Bristol-Myers Squibb aims to use Concerto HealthAI's real-world data, AI platform to speed cancer drug development

Bristol-Myers Squibb entered a partnership with Concerto HealthAI to use the latter's real-world data and artificial intelligence (AI) insights platform as it looks to speed development of new drugs for cancer, the companies reported Thursday. Jeff Conklin, head of business insights and analytics at Bristol-Myers Squibb, said the deal "reinforces our commitment to pursue data science to accelerate disease insights, advance novel study concepts and achieve precision in treatment."

Bristol-Myers Squibb noted that it will use Concerto's real-world data and AI insights platform, called eurekaHealth, to "accelerate insights through novel health economic outcomes and clinical development synthetic control arm studies." Under the agreement, the companies will "advance the use of real-world evidence for regulatory purposes, validate clinical application of AI solutions and execute clinical studies to advance patient care."

Commenting on the deal, Concerto CEO Jeff Elton said the agreement "is a recognition that we have reached a pivot-point for [real-world evidence] – it is not just a tool for generating insights into the current standard of care, but a field in its own right that can lead to optimisation of current treatments and new therapeutic innovations."

According to Concerto, its platform integrates data from several sources including CancerLinQ, a platform developed to collect and analyse real-world data from patients at US healthcare firms and deliver data back to healthcare professionals and researchers. Concerto indicated that it uses CancerLinQ to expand the use of real-world evidence for both pre- and post-approval studies.

The companies noted that the collaboration follows the FDA's commitment last December to promote the use of real-world evidence in the development of new drugs and biologics. Meanwhile, a number of drugmakers have been turning to AI to assist in their drug discovery efforts, with Celgene recently inking a deal to use Exscientia's AI capabilities to hasten the development of small-molecule therapies for programmes in oncology and autoimmunity. The latter firm had previously partnered with companies including Evotec, GlaxoSmithKline, Roche and Sanofi.


To read more Top Story articles, click here.